Plc Glaxosmithkline - Net Worth and Insider Trading

Plc Glaxosmithkline Net Worth

The estimated net worth of Plc Glaxosmithkline is at least $1.5 Billion dollars as of 2024-11-05. Plc Glaxosmithkline is the Former 10% Owner of Principia Biopharma Inc and owns about 2,982,855 shares of Principia Biopharma Inc (PRNB) stock worth over $298 Million. Plc Glaxosmithkline is the 10% Owner of WAVE Life Sciences Ltd and owns about 16,775,691 shares of WAVE Life Sciences Ltd (WVE) stock worth over $227 Million. Plc Glaxosmithkline is also the Director of Turning Point Therapeutics Inc and owns about 2,253,660 shares of Turning Point Therapeutics Inc (TPTX) stock worth over $171 Million. Besides these, Plc Glaxosmithkline also holds CRISPR Therapeutics AG (CRSP) , Morphic Holding Inc (MORF) , Translate Bio Inc (TBIO) , Pandion Therapeutics Inc (PAND) , Progyny Inc (PGNY) , Theravance Biopharma Inc (TBPH) , Bicycle Therapeutics PLC (BCYC) , Anacor Pharmaceuticals Inc (ANAC) , Nkarta Inc (NKTX) , Liquidia Corp (LQDA) , Decibel Therapeutics Inc (DBTX) , Spero Therapeutics Inc (SPRO) , Genocea Biosciences Inc (GNCAQ) , HTG Molecular Diagnostics Inc (HTGMQ) , ChemoCentryx Inc (CCXI) , Amicus Therapeutics Inc (FOLD) , Innoviva Inc (INVA) , Quest Diagnostics Inc (DGX) . Details can be seen in Plc Glaxosmithkline's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Plc Glaxosmithkline has not made any transactions after 2024-09-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Plc Glaxosmithkline

To

Plc Glaxosmithkline Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Plc Glaxosmithkline owns 33 companies in total, including Genocea Biosciences Inc (GNCAQ) , Pandion Therapeutics Inc (PAND) , and Bicycle Therapeutics PLC (BCYC) among others .

Click here to see the complete history of Plc Glaxosmithkline’s form 4 insider trades.

Insider Ownership Summary of Plc Glaxosmithkline

Ticker Comapny Transaction Date Type of Owner
GNCAQ Genocea Biosciences Inc 2020-07-24 10 percent owner
PAND Pandion Therapeutics Inc 2020-07-21 director & 10 percent owner
BCYC Bicycle Therapeutics PLC 2020-07-15 director & 10 percent owner
LIMIT LIMIT 2020-07-14 director & 10 percent owner
LIMIT LIMIT 2016-03-14 10 percent owner
LIMIT LIMIT 2020-05-21 director & 10 percent owner
LIMIT LIMIT 2020-05-20 10 percent owner
LIMIT LIMIT 2020-01-01 director & 10 percent owner
LIMIT LIMIT 2019-10-18 other: Former 10% Owner
LIMIT LIMIT 2019-07-17 10 percent owner
LIMIT LIMIT 2019-07-01 director & 10 percent owner
LIMIT LIMIT 2018-10-16 other: Former 10% holder
LIMIT LIMIT 2018-07-30 other: Former 10% holder
LIMIT LIMIT 2018-07-18 10 percent owner
LIMIT LIMIT 2018-07-17 10 percent owner
LIMIT LIMIT 2018-07-02 10 percent owner
LIMIT LIMIT 2017-06-28 10 percent owner
LIMIT LIMIT 2017-03-27 10 percent owner
LIMIT LIMIT 2016-10-24 10 percent owner
LIMIT LIMIT 2021-05-20 10 percent owner
LIMIT LIMIT 2014-03-26 10 percent owner
LIMIT LIMIT 2014-10-27 10 percent owner
LIMIT LIMIT 2014-02-12 10 percent owner
LIMIT LIMIT 2013-07-23 10 percent owner
LIMIT LIMIT 2012-09-13 10 percent owner
LIMIT LIMIT 2011-01-31 10 percent owner
LIMIT LIMIT 2010-11-24 10 percent owner
LIMIT LIMIT 2021-06-29 10 percent owner
LIMIT LIMIT 2021-02-17 director & 10 percent owner
LIMIT LIMIT 2021-06-16 10 percent owner
LIMIT LIMIT 2021-06-16 10 percent owner
LIMIT LIMIT 2024-09-27 10 percent owner
LIMIT LIMIT 2014-02-04 10 percent owner

Plc Glaxosmithkline Latest Holdings Summary

Plc Glaxosmithkline currently owns a total of 21 stocks. Among these stocks, Plc Glaxosmithkline owns 2,982,855 shares of Principia Biopharma Inc (PRNB) as of October 18, 2019, with a value of $298 Million and a weighting of 19.27%. Plc Glaxosmithkline owns 16,775,691 shares of WAVE Life Sciences Ltd (WVE) as of September 27, 2024, with a value of $227 Million and a weighting of 14.68%. Plc Glaxosmithkline also owns 2,253,660 shares of Turning Point Therapeutics Inc (TPTX) as of May 21, 2020, with a value of $171 Million and a weighting of 11.06%. The other 18 stocks CRISPR Therapeutics AG (CRSP) , Morphic Holding Inc (MORF) , Translate Bio Inc (TBIO) , Pandion Therapeutics Inc (PAND) , Progyny Inc (PGNY) , Theravance Biopharma Inc (TBPH) , Bicycle Therapeutics PLC (BCYC) , Anacor Pharmaceuticals Inc (ANAC) , Nkarta Inc (NKTX) , Liquidia Corp (LQDA) , Decibel Therapeutics Inc (DBTX) , Spero Therapeutics Inc (SPRO) , Genocea Biosciences Inc (GNCAQ) , HTG Molecular Diagnostics Inc (HTGMQ) , ChemoCentryx Inc (CCXI) , Amicus Therapeutics Inc (FOLD) , Innoviva Inc (INVA) , Quest Diagnostics Inc (DGX) have a combined weighting of 54.98% among all his current holdings.

Latest Holdings of Plc Glaxosmithkline

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRNB Principia Biopharma Inc 2019-10-18 2,982,855 100.05 298,434,643
WVE WAVE Life Sciences Ltd 2024-09-27 16,775,691 13.55 227,310,613
TPTX Turning Point Therapeutics Inc 2020-05-21 2,253,660 76.01 171,300,697
CRSP CRISPR Therapeutics AG 2016-10-24 3,220,627 48.07 154,815,540
MORF Morphic Holding Inc 2019-07-01 2,633,772 56.99 150,098,666
TBIO Translate Bio Inc 2018-07-02 3,697,912 37.36 138,153,992
PAND Pandion Therapeutics Inc 2020-07-21 2,248,304 60.05 135,010,655
PGNY Progyny Inc 2020-05-20 6,238,244 15.49 96,630,400
TBPH Theravance Biopharma Inc 2016-03-14 9,644,807 8.18 78,846,297
BCYC Bicycle Therapeutics PLC 2020-07-15 1,910,531 23.76 45,394,217
ANAC Anacor Pharmaceuticals Inc 2010-11-24 2,771,374 9.82 27,214,893
NKTX Nkarta Inc 2020-07-14 3,229,822 3.23 10,432,325
LQDA Liquidia Corp 2018-07-30 624,422 10.25 6,400,326
DBTX Decibel Therapeutics Inc 2021-02-17 1,183,663 4.91 5,811,785
SPRO Spero Therapeutics Inc 2018-07-17 1,934,006 1.32 2,543,218
GNCAQ Genocea Biosciences Inc 2020-07-24 4,626,389 0.00 463
HTGMQ HTG Molecular Diagnostics Inc 2017-03-27 4,404 0.00 2
CCXI ChemoCentryx Inc 2018-10-16 0 51.99 0
FOLD Amicus Therapeutics Inc 2014-10-27 0 11.38 0
INVA Innoviva Inc 2021-05-20 0 19.41 0
DGX Quest Diagnostics Inc 2011-01-31 0 153.53 0

Holding Weightings of Plc Glaxosmithkline


Plc Glaxosmithkline Form 4 Trading Tracker

According to the SEC Form 4 filings, Plc Glaxosmithkline has made a total of 0 transactions in Principia Biopharma Inc (PRNB) over the past 5 years. The most-recent trade in Principia Biopharma Inc is the acquisition of 357,142 shares on October 18, 2019, which cost Plc Glaxosmithkline around $10 Million.

According to the SEC Form 4 filings, Plc Glaxosmithkline has made a total of 2 transactions in WAVE Life Sciences Ltd (WVE) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in WAVE Life Sciences Ltd is the acquisition of 2,791,930 shares on September 27, 2024, which cost Plc Glaxosmithkline around $22 Million.

According to the SEC Form 4 filings, Plc Glaxosmithkline has made a total of 1 transactions in Turning Point Therapeutics Inc (TPTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Turning Point Therapeutics Inc is the acquisition of 83,333 shares on May 21, 2020, which cost Plc Glaxosmithkline around $5 Million.

More details on Plc Glaxosmithkline's insider transactions can be found in the Insider Trading History of Plc Glaxosmithkline table.

Insider Trading History of Plc Glaxosmithkline

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Plc Glaxosmithkline Trading Performance

GuruFocus tracks the stock performance after each of Plc Glaxosmithkline's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Plc Glaxosmithkline is 5.08%. GuruFocus also compares Plc Glaxosmithkline's trading performance to market benchmark return within the same time period. The performance of stocks bought by Plc Glaxosmithkline within 3 months outperforms 12 times out of 24 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Plc Glaxosmithkline's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Plc Glaxosmithkline

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
10 out of 21 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 3.56 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 1.08 LIMIT LIMIT LIMIT LIMIT LIMIT

Plc Glaxosmithkline Ownership Network

Ownership Network List of Plc Glaxosmithkline

No Data

Ownership Network Relation of Plc Glaxosmithkline

Insider Network Chart

Plc Glaxosmithkline Owned Company Details

What does Genocea Biosciences Inc do?

Who are the key executives at Genocea Biosciences Inc?

Plc Glaxosmithkline is the 10 percent owner of Genocea Biosciences Inc. Other key executives at Genocea Biosciences Inc include CHIEF LEGAL & COMPLIANCE OFF Jacquelyn L Sumer , director & President and CEO William D Clark , and CHIEF FINANCIAL OFFICER Diantha Duvall .

Genocea Biosciences Inc (GNCAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genocea Biosciences Inc (GNCAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genocea Biosciences Inc (GNCAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genocea Biosciences Inc (GNCAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Genocea Biosciences Inc Insider Transactions

No Available Data

Plc Glaxosmithkline Mailing Address

Above is the net worth, insider trading, and ownership report for Plc Glaxosmithkline. You might contact Plc Glaxosmithkline via mailing address: 980 Great West Road, Brentford Middlesex X0 Tw8 9gs.